New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:07 EDTMSTXMast Therapeutics reports positive data from MST-188 study
Mast Therapeutics announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 in a model of chronic heart failure. MST-188 resulted in statistically significant and progressive reductions in troponin-I, at both 1 week and 2 weeks after MST-188 administration. Specifically, at 2 weeks post-administration, compared to baseline values, mean reduction troponin was 46.7% for low-dose MST-188 and 48.8% for high-dose MST-188. In contrast, troponin increased 7.7% in the control group.
News For MSTX From The Last 14 Days
Check below for free stories on MSTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:26 EDTMSTXPiper Jaffray to hold a conference
Subscribe for More Information
September 8, 2014
08:01 EDTMSTXMast Therapeutics announces positive results from Phase 2 study of AIR001
Mast Therapeutics reported top-line results from a Phase 2 study of AIR001 inhalation solution for the treatment of pulmonary arterial hypertension. Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance. In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal, which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use